Celltrion Receives EC’s Approval for Yuflyma (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases

 Celltrion Receives EC’s Approval for Yuflyma (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases

Celltrion Receives EC’s Approval for Yuflyma (CT-P17, biosimilar adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases

Shots:

  • The EC approval follows CHMP’s positive recommendation for Yuflyma (high concentration formulation) granted in Dec’2020. The approval covers all 13 intended indications to treat multiple chronic inflammatory diseases
  • The approval is based on analytical, pre/ clinical studies, demonstrating that Yuflyma is comparable to the reference product, in terms of safety, efficacy, PK/PD, and immunogenicity up to 24wks. and 1yr following treatment
  • The company will take ECDRP to minimize lead time to launch the product in the UK and remains committed to delivering innovative and affordable medications

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Fortune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post